具有干细胞亚型成分的肝细胞癌-胆管癌混合型的临床病理意义——与假定的干细胞标志物的表达相关。
Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers.
机构信息
Section of Diagnostic Pathology, Kanazawa University Hospital, Kanazawa 920-8641, Japan.
出版信息
Am J Clin Pathol. 2013 Sep;140(3):329-40. doi: 10.1309/AJCP66AVBANVNTQJ.
OBJECTIVES
To examine the clinicopathologic features of combined hepatocellular-cholangiocarcinoma (HC-CC), which the World Health Organization (WHO) proposed classifying into 2 types, and the expression of delta-like 1 homolog (DLK1), as well as putative stem cell markers, such as NCAM/CD56 and CD133.
METHODS
In this study we examined the expression of stem cell markers using immunohistochemistry.
RESULTS
Thirty-six cases of combined HC-CC were subclassified into 24 cases, with more than 5% stem cell features (group B) and 12 cases with less than 5% stem cell areas (group A). The postoperative overall survival rate was worse for group B than for group A. DLK1 was frequently expressed in group B cases compared with group A, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma cases.
CONCLUSIONS
The 2010 WHO classification seems important for elucidating the pathogenesis of stem cell-related liver cancers.
目的
研究世界卫生组织（WHO）提出的两种分类方法的肝细胞-胆管细胞癌（HC-CC）的临床病理特征，以及 delta-like 1 同源物（DLK1）的表达情况，以及潜在的干细胞标志物，如 NCAM/CD56 和 CD133。
方法
本研究采用免疫组织化学法检测干细胞标志物的表达情况。
结果
36 例混合型 HC-CC 分为 24 例，具有超过 5%的干细胞特征（B 组）和 12 例具有小于 5%的干细胞区域（A 组）。B 组的术后总生存率比 A 组差。与 A 组、肝细胞癌和肝内胆管细胞癌相比，B 组病例中 DLK1 表达更为频繁。
结论
2010 年 WHO 分类似乎对阐明与干细胞相关的肝癌的发病机制很重要。
Zotero 插件